Cartesian Therapeutics, Inc. Common Stock RNAC
i
Market dataready · fetched 2026-11-12T15:19:20.810Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2027-02-19
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-12T15:18:34.519952223Z
FundamentalsSEC EDGAR · ready · as of 2026-09-30 · fetched 2026-11-12T15:19:19.744440+00:00
Cartesian Therapeutics, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | ||||||
| 30Δ | ||||||
| 35Δ | ||||||
| 40Δ | 9.98 | 131.0% | 65.9% | |||
| 45Δ | 9.48 | 122.6% | 59.5% | 7.77 | 138.6% | 21.7% |
| 50Δ | 8.98 | 114.2% | 53.1% | 8.17 | 130.4% | 18.7% |
| 55Δ | 8.48 | 105.8% | 46.8% | 8.57 | 122.1% | 15.6% |
| 60Δ | 7.99 | 97.3% | 40.4% | 8.97 | 113.9% | 12.6% |
| 65Δ | 7.49 | 88.9% | 34.0% | 9.37 | 105.7% | 9.5% |
| 70Δ | 6.99 | 80.5% | 27.6% | 9.77 | 97.4% | 6.5% |
| 75Δ | 6.49 | 72.1% | 21.2% | |||
| 80Δ | 5.99 | 63.7% | 14.8% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
40Δ
- Pseudo strike
- 9.98
- IV
- 131.0%
- B/E move
- 65.9%
- Pseudo strike
- IV
- B/E move
45Δ
- Pseudo strike
- 9.48
- IV
- 122.6%
- B/E move
- 59.5%
- Pseudo strike
- 7.77
- IV
- 138.6%
- B/E move
- 21.7%
50Δ
- Pseudo strike
- 8.98
- IV
- 114.2%
- B/E move
- 53.1%
- Pseudo strike
- 8.17
- IV
- 130.4%
- B/E move
- 18.7%
55Δ
- Pseudo strike
- 8.48
- IV
- 105.8%
- B/E move
- 46.8%
- Pseudo strike
- 8.57
- IV
- 122.1%
- B/E move
- 15.6%
60Δ
- Pseudo strike
- 7.99
- IV
- 97.3%
- B/E move
- 40.4%
- Pseudo strike
- 8.97
- IV
- 113.9%
- B/E move
- 12.6%
65Δ
- Pseudo strike
- 7.49
- IV
- 88.9%
- B/E move
- 34.0%
- Pseudo strike
- 9.37
- IV
- 105.7%
- B/E move
- 9.5%
70Δ
- Pseudo strike
- 6.99
- IV
- 80.5%
- B/E move
- 27.6%
- Pseudo strike
- 9.77
- IV
- 97.4%
- B/E move
- 6.5%
75Δ
- Pseudo strike
- 6.49
- IV
- 72.1%
- B/E move
- 21.2%
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- 5.99
- IV
- 63.7%
- B/E move
- 14.8%
- Pseudo strike
- IV
- B/E move
Options history
No recorded observations
Biotechnology
ROIV
Roivant Sciences Ltd (ROIV) is a transformative biopharmaceutical company focused on advancing drug development and commercialization through a distinctive business model that…
More →RPRX
Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. The company is headquartered in New…
More →RVMD
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is…
More →RXRX
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that decodes biology by integrating technological innovations in biology, chemistry, automation, data…
More →RYTM
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of rare genetic…
More →RZLT
Description unavailable
More →